Safety Update – product information updates
When new safety information comes to light about medicinal products, Swissmedic works closely with marketing authorisation holders to update the corresponding product information (Information for healthcare professionals and Patient information). As a result, healthcare professionals gain timely access to safety-related findings.
The following overview is updated monthly and provides information about selected active substances or active substance groups whose Information for healthcare professionals has been, or will be, updated with new safety-related information.
These updates are currently available in German, French, or Italian.
Important information
The updates to product information for generics are delayed as these are adapted at a later date to those of the original product. Please note that this is not a complete overview since not all changes to individual Information for healthcare professionals are presented in detail, and the safety information listed for individual medicinal products containing an active substance or substance class may already be included in the Information for healthcare professionals.
The information is subject to possible legal remedies. In all cases, the current versions of the Information for healthcare professionals available at www.swissmedicinfo-pro.ch are binding.
All Safety Updates since November 2025
Safety of medicines – always up to date
Subscribe to the newsletter
The “Safety of medicines” newsletter provides monthly updates on the most important revisions to the product information for selected active substances or substance groups.
| Active substance(s) |
New safety information |
Updated section(s) |
(D)HPC |
| Apixaban |
Alopecia |
Undesirable effects |
– |
| Bictegravir |
Interaction with zinc: It is recommended that they are taken at different times. |
Interactions |
– |
| Bictegravir |
Weight gain |
Warnings and precautions; Undesirable effects |
– |
| Caspofungin |
Use of polyacrylonitrile membranes should be avoided in patients on continuous renal replacement therapy and treatment with caspofungin; an alternative membrane or a different antifungal agent should be used instead. |
Warnings and precautions |
DHPC – Caspofungin Labatec®, Caspofungin Leman®, Caspofungin Mepha®, Caspofungin Viatris, Caspofungin Sandoz® eco (Caspofungin) |
| CFTR modulators |
Changes in behaviour, anxiety, insomnia |
Warnings and precautions; Undesirable effects |
– |
| Chenodeoxycholic acid |
Elevated transaminases, jaundice |
Undesirable effects |
– |
| Ciltacabtagene autoleucel |
Reactivation of the John Cunningham (JC) virus |
Warnings and precautions |
– |
| Clozapine |
Revised blood count monitoring recommendations |
Dosage/use; Contraindications; Warnings and precautions; Undesirable effects |
DHPC – Clozapin |
| Clozapine |
Interaction with valproate: increased risk of myocarditis. |
Warnings and precautions |
– |
| Clozapine |
Appendicitis |
Warnings and precautions; Undesirable effects |
– |
| Clozapine |
Haematological malignancies |
Undesirable effects |
– |
| Combination: elexacaftor + ivacaftor + tezacaftor |
Hypersensitivity |
Undesirable effects |
– |
| Combination: nirmatrelvir + ritonavir |
Concomitant use with cariprazine is contraindicated. |
Contraindications; Interactions |
– |
| Domperidone |
Phaeochromocytoma |
Contraindications |
DHPC – Domperidon axapharm lingual®, Domperidon lingual Spirig HC®, Domperidon-Mepha® oro, Motilium®, Motilium lingual®, Motilium lingual Gastrosan® (Domperidon) |
| Etoposide |
Angioedema |
Undesirable effects |
– |
| Inclisiran |
Hypersensitivity |
Undesirable effects |
– |
| Tenofovir alafenamide |
Excretion of tenofovir alafenamide in breast milk |
Pregnancy, lactation |
– |
| Tezepelumab |
Anaphylaxis: patients should be monitored after administration. |
Warnings and precautions |
– |
| Tezepelumab |
Treat existing severe infections before starting therapy; in case of a severe infection, discontinue therapy until resolved. |
Warnings and precautions |
– |
| Tranexamic acid |
Fixed drug eruption |
Undesirable effects |
– |
| Tranexamic acid |
Acute renal cortical necrosis |
Undesirable effects |
– |
| Tranexamic acid |
Medication errors due to incorrect administration route: tranexamic acid may only be administered intravenously. |
Dosage/use; Contraindications; Warnings and precautions; Other information |
– |
